In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocyes because 

genetically engineered lymphocytes are not immortal cells

gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages

lymphocytes from patient’s blood are grown in culture, outside the body

retroviral vector is introduced into these lymphocytes